Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0684249 (lung carcinoma)
 23,830 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Murine leukemia L1210 cells contain active glucosamine 6-phosphate synthase inhibited by N3-4-methoxyfumaroyl-L-2,3-diaminopropanoic acid (FMDP). However, FMDP-peptides do not exhibit any cytotoxicity against these cells, HeLa S3 human cervical carcinoma cells, and LL2 murine Lewis lung carcinoma cells. It is suggested that the lack of cytotoxicity of FMDP-peptides, in spite of good drug uptake and the presence of target enzyme might be due to the poor rate of peptides cleavage by the intracellular peptidases.
Acta Biochim Pol 1991
PMID:The influence of L-norvalyl-N3-4-methoxyfumaroyl-L-2,3-diaminopropanoic acid, an antifungal agent, on mammalian cells in tissue culture. 181 30

In order to gain an insight into interactions between human cancer and the surrounding host tissues, surgical samples of lung carcinoma of distinct histological types were examined for the expression of extracellular matrix (ECM) proteins and very late antigen (VLA) integrins, by means of a panel of monoclonal antibodies and immunohistochemistry of frozen tissue sections. It has been found that fibronectin (FN), tenascin (TN) and to a lesser degree collagen IV were abundant in the immediate vicinity of the tumor, but only TN penetrated tumor mass. FN isoforms were scarce or undetectable within the tumor area. The walls of blood vessels in the vicinity of the tumor showed increased an expression of collagen IV and laminin. The latter was occasionally absent within the basal membrane of cancer cells. The expression of EMC proteins was inversely proportional to the intensity of mononuclear tumor infiltrating cells (TIC). VLA integrins were present on both types of the cells: TIC and tumor cells. Percentage of positive TIC varied from 20% to 70%, depending on VLA integrin tested. VLA-3 was demonstrated on most of the cells of squamous carcinoma, but was almost absent on those of anaplastic small cell carcinoma one. In metastatic lymph node, VLA-4 was strongly expressed on tumor cells comparing to lymphoid ones. These data show that VLA integrins and their EMC ligands play apparently an important, but still obscure role in the interactions between lung carcinoma and its host.
Pol J Pathol 1995
PMID:Extracellular matrix proteins and VLA integrins expression in the microenvironment of human lung carcinoma. 754 97

Microelements metabolic disorders, including copper and zinc, constitute an important field of cancer studies. Efforts are undertaken to identify cancer markers. Found changes in plasma copper and zinc levels in patients with lung carcinoma may have clinical implications, and help in the diagnosis despite the fact that there are no reports in the literature confirming specificity of these two elements for lung carcinoma. Plasma copper and zinc levels were determined in blood samples of 94 patients with lung carcinoma with atomic absorption technique. The obtained results were compared with those in 20 healthy blood donors, and were analysed statistically and plotted graphically. Statistically significant differences in patient's plasma vs control group were noted.
Pol Tyg Lek
PMID:[Level of copper and zinc in plasma of patients with lung cancer]. 770 69

Own concept of small cell lung carcinoma (SCLC) chemotherapy with multidrug regimen including ifosfamide, adriamycin, and etoposide is presented. In the pilot trial, 67% of remissions in patients with localized, and 33% in patients with disseminated neoplastic process were achieved. Proposed therapy has moderate toxicity, markedly lower than that of the regimen including cis-platin. No nephrotoxicity is worth emphasizing. The authors suggest that proposed regimen may be of value in patients in whom combined chemo- and radiotherapy is foreseen.
Pol Tyg Lek
PMID:[Use of ifosfamide in multidrug therapy of small cell lung carcinoma]. 770 71

Prognostic factors for long term survival were analyzed in a group of 719 patients with small cell lung carcinoma treated within 4 consecutive prospective multicenter trials between 1981 and 1990. 74 patients (10.3%) survived more than 2 years; 30 of them (4.2%) with no evidence of disease. The most significant determinator of prolonged survival was extent of disease: 13.9% (59/424) of patients with limited disease vs. 5.1% (15/295) with extensive disease survived more than 2 years (p < 0.001). Of 138 female patients 24 (17.4%) were long term survivors, compared to 8.6% (50/581) of males (p < 0.01). Initial good performance status and no weight loss were also found to be correlated with long term survival. Of the group of 2-year survivors 51 patients subsequently died (median survival duration 31 months), 10 are alive with cancer or are lost to follow up and 13 are in complete remission with median follow up of 64 months. 20 patients (3.8%) survived more than 5 years. This study confirms the possibility of cure in SCLC, especially in patients with favorable prognostic factors.
Pneumonol Alergol Pol 1994
PMID:[Analysis of prognostic factors for long term survival in patients with small cell lung cancer]. 792 Feb 72

The study aimed at evaluating SCC-Ag in patients with NSCLC, especially its predictive value following radical lung surgery. The study involved 70 patients with NSCLC and 48 patients with non-cancerous lesions to the lungs. SCC-Ag was assayed with Imx technique supplied by Abbott. Serum was tested before and 3 years after surgery. The results were analysed statistically with Wilcoxon-Fisher test. Elevated SCC-Ag levels were found in 45.7% of patients with NSCLC and in 4.1% pf patients with non-cancerous lesions. An increase in this antigen level was most frequent in patients with squamous-cell lung carcinoma (65.7%) and percentage of increased values was higher in more advanced stages of the disease (40% in I stage, 66.7% in II, and 78.9% in the III stage). During a 3-year follow-up, a relationship of recurrences or metastases and SCC-Ag levels was noted. Recurrence or metastases were more frequent when antigen levels were increased both before surgery and in postoperative period. The same relationship was seen when normal values before surgery increased after surgical treatment.
Pol Tyg Lek
PMID:[SCC-Ag antigen in serum of patients with primary non-small cell lung carcinoma]. 800 46

The correlation between response to chemotherapy and the serum level of neuron specific enolase NSE as well as value of the test for predicting relapse has been evaluated in 41 patients with small cell lung carcinoma (SCLC). A significant decrease of the mean NSE level in comparison with the pretreatment value was observed (p = 0.01). At the time of relapse the mean level increased significantly (p = 0.005). In 9 out of 19 responders to chemotherapy (47.3%) increase of the NSE level above the normal value preceded clinically diagnosed relapse by 3-6 weeks. These results demonstrate the usefulness of the test in treatment monitoring of patients with SCLC.
Pneumonol Alergol Pol 1993
PMID:[Treatment monitoring of patients with small cell lung cancer by determining levels of serum neuron specific enolase]. 838 60

The serum levels of cytokeratin-19 were measured in 116 patients--96 with NSCLC and 20 with non-malignant lung diseases. The reference group consisted of 60 healthy volunteers--30 smokers and 30 non-smokers. Significantly elevated Cyfra 21-1 values were observed in NSCLC. There was not a correlation between of cytokeratin-19 serum levels and histologic types of lung carcinoma. Cyfra 21-1 concentrations generally increased with stage of diseases and the highest were in patients with evidence of distant metastases. In NSCLC, the distribution of Cyfra 21-1 varied significantly according to the performance status of NSCLC patients.
Pneumonol Alergol Pol 1995
PMID:[Level of cytokeratin-19 in serum of patients with non small cell lung cancer]. 861 76

Previously we have found that administration of thiorphan alone or in combination with bestatin exerts antitumor effect in mice, including reduction of B16 melanoma tumor growth and prolongation of survival time. These data prompted us to extend our studies to estimate the effect of treatment with thiorphan, captopril and bestatin on lung metastases in mice. Administration of thiorphan alone at a dose of 25 micrograms/mouse or in combination with bestatin (50 micrograms) or captopril (5 mg/mouse) decreased the number of spontaneous metastases in lungs of Lewis lung carcinoma bearing mice. Neither the injections of bestatin, captopril nor bestatin in combination with captopril influenced the number of lung tumor colonies. Treatment with thiorphan at a dose 25 micrograms augmented cytotoxic activity of natural killer (NK) cells and macrophages. These observations explain partly the mechanism of action of thiorphan.
Pol J Pharmacol
PMID:Effects of thiorphan, bestatin and captopril on the Lewis lung carcinoma metastases in mice. 886 34

Patients suffering from cancer (responsive to chemotherapy) are usually treated with a combination of anticancer drugs. In our previous studies, we found that captopril exerted antitumor action on Lewis lung carcinoma (LLC) in mice. This prompted us to evaluate the antitumor effect of captopril combined with cyclophosphamide. BD1F1 mice with LLC received two injections of captopril (5 mg/mouse) at a 1 h interval. Two hours later they were injected with cyclophosphamide (6 mg/mouse). Captopril pretreatment augmented the antitumor action of cyclophosphamide expressed as the survival time and the number of cured mice. Captopril given for five days before cyclophosphamide treatment did not change the antitumor activity of cyclophosphamide.
Pol J Pharmacol
PMID:Captopril augments antitumor activity of cyclophosphamide in mice. 911 63


1 2 3 4 5 Next >>